Podcasts about Paroxetine

In this powerful and honest episode of The Penis Project Podcast, Melissa Hadley Barrett speaks with Dave and his partner Jen about their journey dealing with premature ejaculation (PE) — a common but often misunderstood sexual health condition affecting many men and couples.  Dave opens up about his experience living with PE since adolescence, the impact it had on his confidence and relationship, and how alcohol became a coping mechanism. With courage and persistence, Dave eventually found the right healthcare support, the right SSRI medication, and a path forward that improved both his sexual function and emotional connection with his partner.  Together, Melissa, Dave and Jen dive deep into the emotional, psychological, and physical sides of premature ejaculation — offering valuable insights for men, couples, and practitioners alike.  In This Episode, We Cover:  What premature ejaculation really is – and what it isn't  The difference between primary and secondary PE  Why many men are misinformed or dismissed by health professionals  The impact of PE on relationships, communication, and self-esteem  Dave's journey through trial-and-error with various SSRIs: Priligy (Dapoxetine), Paroxetine, Fluoxetine and Escitalopram (Lexapro)  The hidden cost of online treatment platforms – and why cheaper, more ethical options exist  How the right treatment changed everything – from sex drive to emotional closeness  Jen's reflections as a partner and the importance of support, understanding and touch  How couples can reconnect through small changes, time together, and deeper conversations  Melissa's recommendation: Sanctuary of Ananda for Tantra-based relationship connection workshops  Key Takeaways:    Premature ejaculation is more common than you think – and it's treatable  Not all SSRIs are the same. Personalised treatment matters.  The emotional and relational impacts of PE are real – and deserve attention  There's no shame in asking for help. Support is available, affordable, and effective.  Sexual health is about more than performance – it's about connection, confidence, and communication  Expert Insight from Melissa Hadley Barrett:  “If PE is affecting your confidence, relationship or sex life – there is help. You don't need to suffer in silence. With the right support, treatment can be simple, effective, and affordable.”  Resources & Links:  Book a telehealth consult with our sexual health nurse practitioners at Restorative Health Clinic  Learn more about Sanctuary of Ananda – Tantra and connection workshops for couples  Listen to Cam Fraser's podcast on modern masculinity and sexual wellness  For more information check out our websites www.rshealth.com.au , www.makehardeasy.com.au and www.melissahadleybarrett.com.au   Listen & Subscribe  If you found this episode helpful, don't forget to subscribe, rate, and review the podcast! Your feedback helps us continue bringing important conversations to light. Search for The Penis Project Podcast on Spotify, Apple Podcasts, or your favourite podcast app.  Connect With Us  Have questions or want to share your story?  Email: admin@melissahadleybarrett.com  Website: www.rshealth.com.au  Websites:  https://rshealth.com.au/  All genders  https://makehardeasy.com.au   https://melissahadleybarrett.com   http://www.menshealthphysiotherapy.com.au/  http://prost.com.au/     Facebook:  https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/  https://www.facebook.com/profile.php?id=100085146627814    Instagram:  https://www.instagram.com/melissahadleybarrett/  https://www.instagram.com/restorativehealth.clinic/  TikTok: @melissahadleybarrett  YouTube: Melissa Hadley Barrett  Linkedin:  https://www.linkedin.com/in/melissa-hadley-barrett/   TEDX  https://www.youtube.com/watch?v=IjHj1YTmLoA 

Psychiatric surviver who struggled with antidepressants, but ultimately successful at tapering off all drugs including Paroxetine, and Sertraline. Tomasz now guides individuals on the path to recovery from antidepressant withdrawal and PSSD. Visit Tomasz's website https://protracted-withdrawal.com/ ✨Get AD FREE early access and your name in videos through our Patreon! https://patreon.com/psychologyis

On this episode, we hear from Vincent Schmitt and Yoko Motohama, parents of Romain, a 16-year-old boy who tragically ended his life in 2021 after being prescribed a high dose of Paxil — known in France as Paroxetine — and suffering the effects of akathisia for several agonizing months.Yoko Motohama was born in Japan and earned a Ph.D. in computer science. She did postdoctoral research in the United Kingdom and spent a decade in Japan as an entrepreneur importing French wines.Her husband, Vincent Schmitt, a native of France, also earned a Ph.D. and became a lecturer in mathematics and computer science at the University of Leicester. Now based in France, close to Lyon, Vincent focuses on applied mathematics in the research department of a multinational company.Romain Schmitt was born October 12th, 2004, in Leicester, United Kingdom, the son of Vincent and Yoko. When the boy was four years old his parents decided to relocate the family — which also included Romain's younger sister — to France, and not long after that to the Japanese countryside. Romain had already learned English and French and now became a fluent speaker of Japanese. After nine years the family returned to France, in 2018, where 13-year-old Romain started the third year of middle school. He had a good mind for math and physics and was interested as well in geography, philosophy, politics, and even nuclear science and energy, which his grandfather taught him about. Romain was also a good swimmer, played rugby and tennis, and aspired to become a professional soccer player, like his idol Cristiano Ronaldo. His love of the game even inspired Romain to master a fourth language, German, so that he could better follow his favorite team, Bayern Munich.READ THE FULL EPISODE 18 TRANSCRIPT

In this episode, Tristan J. Barber, MA, MD, FRCP, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating PTSD in people with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, sharing their own experiences and approaches to thinking about PTSD, structuring appointments, and integrating care. Presenters:Tristan J. Barber, MA, MD, FRCPConsultant in HIV MedicineRoyal Free London NHS Foundation TrustHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonLondon, United KingdomGlenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides:https://bit.ly/4dBu929Program:https://bit.ly/3WB2VCO

On this episode of the Real Life Pharmacology podcast, I discuss drugs 31-35 of the top 200 drugs. Ethinyl estradiol/drospirenone is a combined oral contraceptive used for birth control purposes. Hydralazine is a direct vasodilatory that can be used for hypertension and heart failure. Benztropine is an older anticholinergic medication originally indicated for Parkinson's disease but most commonly used to manage EPS symptoms from dopamine-blocking agents such as antipsychotics. Tussionex is a combination medication of chlorpheniramine and hydrocodone. It is used to help alleviate cough. Paroxetine is an SSRI used for the treatment of depression, anxiety, and other psychiatric disorders.

Today's sponsor of the Top 10 SSRI Drug Interactions podcast is FreedAI. Freed listens, transcribes, and writes medical documentation for you. In this podcast episode, I discuss how to navigate SSRI drug interactions and identify some of the most common medications that have additive serotonergic activity. SSRIs have antiplatelet activity. I discuss how to navigate using other medications that may increase bleed risk in combination with SSRIs. Paroxetine and fluoxetine inhibit CYP2D6 I discuss how this can affect the benefits of tamoxifen therapy. Fluvoxamine is a nasty medication with regard to the number of and significance of drug interactions. I outline important fluvoxamine interactions in this podcast episode.

Join us for a brief discussion on Luvox and Paxil.

High Yield Psychiatric Medications Antidepressants Review for your PANCE, PANRE, Eor's and other Physician Assistant exams. Review includes SSRI's, SNRIs, TCAs, MAOIs, Atypical antidepressants, Serotonin modulators. TrueLearn PANCE/PANRE SmartBank:https://truelearn.referralrock.com/l/CRAMTHEPANCE/Discount code for 20% off: CRAMTHEPANCEIncluded in review: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Desvenlafaxine, Duloxetine, Levomilnacipran , Milnacipran, Venlafaxine, Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine, Desipramine, Nortriptyline, Protriptyline, Tranylcypromine, Isocarboxazid, Phenelzine Selegiline, Bupropion, Mirtazapine, Trazodone

In this issue:Spironolactone for acne - does it work?Paroxetine for erythema of rosaceaMethotrexate monitoring schedules - should we rethink 3 monthly bloods?Long-term neurocognitive affects of propranololNICE eczema updateWhat's Multinucleate Cell Angiohistiocytoma?+ more…

The 2023 Menopause Society  (NAMS) position statement regarding the non-hormonal treatment of Vasomotor Symptoms- hot flashes and night sweats- was just released. Position statements are expert analyses of current studies in order to determine recommendations based on science, as opposed to what the latest Tik Tok star or celebrity is promoting. Because new studies are constantly being published, there is always new information to inform those recommendations, which is why position statements need to periodically get updated.  Because the position statement is very extensive and long, I have divided it into 3 episodes.  Part 1- Non-hormonal prescription options Part 2 -Over the counter botanicals and dietary supplements  Part 3- Lifestyle; mind-body techniques; acupuncture and cooling devices.  In this episode, I am covering non-hormonal prescription options. My guest is one of the authors of The Menopause Society position statement, Dr. Chrisandra Shufelt. Dr. Shufelt is a certified menopause practitioner of The Menopause Society, the Chair of the Division of General Internal Medicine, Senior Consultant at the Mayo Clinic Women's Health, and Associate Director of Women's Health Research Center at Mayo Clinic in Jacksonville, Florida. The drugs discussed include: Selective Serotonin Reuptake Inhibitors (SSRI) such as Paroxetine, Citalopram, Escitalopram Selective Norepinephrine Reuptake Inhibitors (SNRI) such as Desvenlafaxine, Venlafaxine Gabapentin  Pre-gabalin Clonidine Oxybutynin Suvorexant  Fezolinetant And stick around for the wrap-up at the end. I summarize the recommendations. Other relevant episodes:  Episode 2:Think Your Hot Flashes Can't Kill You? Think Again! Episode 31 The TRUTH About Hormone Therapy: Does it CAUSE or Does it PREVENT Breast Cancer? Episode 77 Fezolinetant! A New Non-Hormonal Hot Flash Drug  For more information:   Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Lauren Streicher, MD is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, and the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause. She is a certified menopause practitioner of the North American Menopause Society.  Sign up to receive DR. STREICHER'S FREE NEWSLETTER Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.  Subscribe and Follow Dr. Streicher on  DrStreicher.com Instagram @DrStreich Twitter @DrStreicher Facebook  @DrStreicher YouTube  DrStreicherTV Books by Lauren Streicher, MD  Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy

What strain caused this year's early RSV activity? Find out about this and more in today's PVRoundup podcast.

Download the cheat: https://bit.ly/50-meds  View the lesson:     Generic Name paroxetine Trade Name Paxil Indication major depressive disorder, OCD, anxiety, PTSD Action block reuptake of serotonin in CNS Therapeutic Class antianxiety agent, antidepressant Pharmacologic Class SSRI Nursing Considerations • do not use with MAOIs • can cause neurolyptic malignant syndrome, suicidal thoughts, serotonin syndrome, constipation, diarrhea, insomnia • decrease effectiveness of digoxin • increase bleeding with warfarin • assess for suicidal thoughts

In this episode, Dr. Zach April returns to review the SSRI's. These are some of the best treatment options for mood. We talk about what to expect in general with these medications and review some of the individual medicines including sertraline (Zoloft), fluoxetine (Prozac) and escitalopram (Lexapro) to name a few.  A disclaimer, we're providing general guidance but everyone is different and you should always discuss with your health care professional management of any disease and therapy before trying anything you discover from a source on the internet (including this podcast)

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the October 11, 2022, issue.

Paroxetine, also known as Paxil, is a Selective Serotonin-Reuptake Inhibitor (SSRI) used in the treatment of various mood disorders. Mood disorders such as major depressive disorder, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder, PTSD, premenstrual dysphoric disorder, and mild-moderate menopausal vasomotor symptoms. Dosing varies by indication but commonly between 20-50 mg PO qam for immediate release dosage forms and around 12.5-75 mg PO qam for the extended release dosage forms. The absorption of paroxetine is not affected by food and is completely bioavailable after oral administration. The half-life elimination is around 21-24 hours. There is a black box warning for suicidality with the increased risk seen in children, adolescents, and young adults. Always weigh the risks vs benefits when using the medication. Amazon Affiliate link: https://amzn.to/31OkKVe for NAPLEX Math Review: The Foundation of a Logical NAPLEX Prep Strategy. FREE Drug Card Sheet is available for this episode at DrugCardsDaily.com along with ALL past FREE drug card sheets! Please SUBSCRIBE, FOLLOW, and RATE on Spotify, Apple Podcasts, or wherever your favorite place to listen to podcasts are. I'd really appreciate hearing from you! Leave a voice message at anchor.fm/drugcardsdaily or find me on most all socials @drugcardsdaily or send an email to contact.drugcardsdaily@gmail.com to leave feedback, request a drug, or say hello! DISCLAIMER: This content may contain sponsored content or the use of affiliate links. Partnerships, sponsorships, and the use of affiliate links provide monetary commissions for Drug Cards Daily at no cost to you! This is done in order to keep providing as much free content to everyone that comes to Drug Cards Daily. Thanks for your support! Drug Cards Daily provides drug information for educational and entertainment use. The information provided is not intended to be a sole source of drug information that is to be acted upon for patient care. If there are drug-related patient care concerns please contact your primary care Physician or local Pharmacist. --- Send in a voice message: https://anchor.fm/drugcardsdaily/message

This week we talk with Professor Jim van Os and Doctor Peter Groot about their latest study which looks at the effectiveness of tapering strips to help people get off antidepressant drugs. Jim van Os is Professor of Psychiatric Epidemiology and Public Mental Health at Utrecht University Medical Centre, the Netherlands and Peter Groot works with the User Research Centre of UMC Utrecht. They both are involved with the development and study of tapering strips which are pre-packaged, gradually reducing dosage tablets that facilitate tapered withdrawal from psychiatric drugs. In this interview, we discuss their latest research paper which examines tapering strips in real-world use. *** Download Mad in America's new mobile app here. Available for Apple or Android mobile devices, keep up to date as we publish new audio interviews or browse our archive.  

Paroxetine (Paxil) is an SSRI that can be used in the management of depression. I discuss more on paroxetine pharmacology in this episode. Because paroxetine has some modest anticholinergic effects, it does show up on the Beers list as a potentially inappropriate medication. By inhibiting CYP2D6, paroxetine can have numerous drug interactions. Drugs like atomoxetine, aripiprazole, and metoclopramide can all have their concentrations increased. Tamoxifen is activated by CYP2D6 and paroxetine can ultimately reduce the effectiveness of the medication.

#neuroscience #psilocybin #MDMA #depression #psychedelicmedicine From NeuroBeer #4 - streamed live June 15, 2020. Full conversation: https://youtu.be/yhxyuBLiLs8 Do you need to have a psychedelic trip to experience the beneficial therapeutic actions of psychedelics? How long does it take for psychedelic drugs like MDMA or magic mushrooms (psilocybin) to have therapeutic effects for depression or ptsd treatment? How long do these antidepressant actions of MDMA & psilocybin last? And How do these psychedelic drugs produce their beneficial effects in the brain to begin with? Serotonin receptors vs metabotropic glutamate receptors involved? These highly anticipated results follow-up with patients treated with MDMA-assisted psychotherapy 1+ years after treatment to evaluate how long the benefits last for.  These freshly published results are derived from six separate phase 2 clinical trials that were published June 3rd in the journal Psychopharmacology.We're a group of Canadian neuroscientists reviewing the latest news, events and scholarly publications from this week in neuroscience and beyond! In each NeuroDrugs live stream we review classics in the field of addiction neuroscience, as well as newly published articles on a weekly basis. In this clip we comment on the recent phase-2 follow up studies from the Multidisciplinary Association For Psychedelic Studies (MAPS). In September 2019 the first results from pooled analyses of 6 double blinded and randomized studies assessing MDMA for PTSD management entitled, "Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline". More than 1 year has passed since the initial trials were completed, and in June 2020 the  results from the 1+ year follow up study of these same individuals were reported. We explore these results and possible mechanisms underlying MDMA and psilocybin assisted psychotherapy for depression and ptsd. open access article phase-2 follow up study: https://link.springer.com/article/10.1007/s00213-020-05548-2 Original Phase 2 pooled analysis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751381/ Additional resources from MAPS: https://maps.org/research/mdma/ptsd/phase3&https://maps.org/research/mdma/mdma-research-timelineJoin us for NeuroBeer every Monday (8pm EDT) & NeuroDrugs every Wednesday (9pm EDT) on YouTube for the largest interactive live streaming journal club & contribute to the conversation! Stay tuned to stay up to date with the latest in neuroscience / general science news! A Production of First-Person SciencePlease subscribe @ www.youtube.com/firstpersonsciencepodcast if you enjoy our content, and share it with friend and platforms that might be interested! It goes a long way in helping us stamp out misinformation in neuroscience media!  

This week on MIA Radio, we interview Wendy Dolin founder of the MISSD foundation. MISSD stands for Medication-Induced Suicide Prevention and Education Foundation in Memory of Stewart Dolin. In 2010, Wendy’s husband Stewart Dolin was prescribed Paxil (paroxetine), a selective serotonin reuptake inhibitor ("SSRI") for mild situational anxiety. Within days, Stewart's anxiety became worse. He felt restless and had trouble sleeping. On July 15, 2010, just six days after beginning the medication, following a regular lunch with a business associate, Stewart left his office and walked to a nearby train station, despite not being a regular commuter. A registered nurse who was also on the platform later reported seeing Stewart pacing back and forth and looking very agitated. As a train approached, Stewart ended his life. Founded in 2011, MISSD is a unique non-profit organization dedicated to honoring the memory of Stewart and others by raising awareness and educating the public about the dangers of akathisia. MISSD aims to ensure that people suffering from akathisia's symptoms are accurately diagnosed so that needless deaths are prevented. Relevant Links: Medication-Induced Suicide Prevention and Education Foundation in Memory of Stewart Dolin MISSD on YouTube MISSD Handout MISSD Free one-hour Continuing Ed Course Akathisia Stories - MISSD Podcast (Apple Podcasts, Spotify) NYC Subway Ads Take Akathisia Out of the Darkness Wendy Dolin Takes on GlaxoSmithKline And Wins — For Now at Least Stewart Dolin’s Widow Loses $3 Million Verdict for Paxil Suicide on Appeal

This month - with about 1 in 10 people in the UK on antidepressant drugs, we're asking what's it like to come off of these medications? How well is this change managed? And how can this be improved? Like this podcast? Please help us by supporting the Naked Scientists

This month - with about 1 in 10 people in the UK on antidepressant drugs, we're asking what's it like to come off of these medications? How well is this change managed? And how can this be improved? Like this podcast? Please help us by supporting the Naked Scientists

“I've tried a lot of things trying to feel better: Meditation. Hot yoga. Cycling. Saunas. Cold showers. More sleep. Less sleep. Acupuncture. Therapy. I tried giving up caffeine and it was awful! I believe in the power of a cup of tea.” — Acclaimed poet and author Ashleigh Young is tired of the side-effects of her depression medication. But what do you do when trying to quit a drug makes you feel worse than ever? * Content warning: Strong language; discussion of suicide. * If you want to talk to a trained counsellor, call or text for free to 1737. * www.stuff.co.nz/outofmymind

“I’ve tried a lot of things trying to feel better: Meditation. Hot yoga. Cycling. Saunas. Cold showers. More sleep. Less sleep. Acupuncture. Therapy. I tried giving up caffeine and it was awful! I believe in the power of a cup of tea.”— Acclaimed poet and author Ashleigh Young is tired of the side-effects of her depression medication. But what do you do when trying to quit a drug makes you feel worse than ever?* Content warning: Strong language; discussion of suicide.* If you want to talk to a trained counsellor, call or text for free to 1737.* www.stuff.co.nz/outofmymind

Porpoise Crispy Podcast Volume #8 Episode #5 Paroxetine (Paxil, Seroxat) Curated by Megs and John March 9, 2019        The Pocket Version of  Volume Eight Number Four Filler Song: Reiter’s Syndrome Errors of MetabolismPlay In Music: Ghost Instrumental  Prof                   Friction  Shame  Songs of Praise Antepoc  Duchess Says In a FUNG Day T King of Nothing  Old Time Relijun Witchcraft Rebellion Axolotl  The Veils Total Depravity A House On Fire  TRAAMS A House on Fire Take Up Thy Stethoscope And Walk  Ty Segall& Mikal Cronin  Reverse Shark Attack I Don't Know About You or Your Band  Super Thief Stuck Suzuki  Zack Mexico Get Rich and Live Forever Sidewalk  Frankie and the Witch Fingers Sidewalk Bench Drop  Secret Smoker Terminal Architecture       The Pocket Version of Volume Eight Number Five The pCrispy is only an hour of music so I know you’ve got time to enjoy to these bad asses of the Internets:  The Westerino ShowFunkytown BayerclanSquirreling PodcastSecretly Timid    

AP: Welcome to the Growing Healthy Podcast.  Today we are fortunate to have Dr. Kelsey Mills with us to talk about Menopause!!  Dr. Mills is an obstetrician and gynecologist who has extra training in the Hot topic of Menopause!  Thanks for joining us Kelsey!    KM: Thanks Alicia, it is my pleasure to chat with you today!  This is a topic that can get women all fired up!     AP: Why don’t we start with the basics; what is menopause?     KM: That’s a great place to start.  Menopause is defined as the permanent absence of menstrual periods for one year, in the absence of other reasons for a period to stop, such as pregnancy. We have had a couple women tricked into thinking they were in menopause when in fact they were pregnant!      AP:  What a surprise that would be!!! Can you tell us a little more about Menopause.      KM: The average age of menopause in Canada is 51.4 and anything after 40 is in fact in the realm of normal. If a woman enters menopause under the age of 40, we search for other diseases, or reasons why that could happen. In natural menopause, a woman stops having periods because her ovaries have essentially used up their pool of eggs (oocytes) and are no longer ovulating each month. Therefore, there isn’t an episode of bleeding that follows ovulation, so all bleeding stops. When women don’t ovulate anymore, there are much lower levels of circulating estrogens in their body which may or may not result in menopausal symptoms.     AP:  But the transition is not necessarily an on/off switch is it....    KM: Nope...it sure isn’t!  On average, women start to experience symptoms of perimenopause for 4-5 years prior to not getting a menstrual period any more.  These symptoms can include irregular or erratic cycles, cycles that fluctuate in heaviness (one month light, one month very heavy), mood changes, hot flashes, night sweats, sleep disturbances and vaginal dryness.       AP: I often have women coming in around that time with musculoskeletal complaints as well....    KM: There are some other common concerns that happen around the time of menopause and certainly increase with aging, like “brain fog”, memory changes, hair loss, weight gain, and muscle and joint pains.  AP:  So lets talk about the menopause-specific symptoms a bit more and how we can manage them.      KM: Great.  So I find that the symptom that bothers women the most, are what we call “vasomotor symptoms” which include the hot flashes and night sweats. We know that about 80% of women in the menopausal transition experience hot flashes, but unfortunately only about 20% of those women will seek medical attention for them. Studies have shown that women find it difficult to discuss menopausal concerns with their primary care providers, and in particular find discussing vulvo-vaginal or sexual symptoms to be the most challenging. But back to hot flashes, these are generally described as a feeling of heat starting in the chest and then spreading over the upper body, face and neck. They can be accompanied by heart palpitations and sweating, and they generally last for 2-4 minutes. Hot flashes are so interesting, because some women never experience them, and some women will flash several times an hour in menopause. Hot flashes can also be different woman to woman; some women describe a prickling or skin-crawling sensation, some women describe a sense of impending doom! This is serious stuff. Menopause researchers used to believe that hot flashes only lasted for 4-5 years, but we now know that they can last much longer, perhaps 8 years on average, and some women will flash for the remainder of their life.      AP: Are there any factors that can make it more likely that women will have worse hot flashes?     KM: Well we know obesity and smoking both increase the risk of hot flashes. Interestingly, certain ethnic backgrounds, such as being of African descent, may make a woman more likely to have hot flashes.     AP: Hot flashes can happen at night as well....often drenching beds with sweat etc.  and this leads into our next symptoms of menopause....sleep disturbance!  We know that about 40% of women struggle with sleep in the menopause transition - this can be related to hot flashes, or our next topic....mood changes - namely depression.  They can also be related to things like restless legs or sleep apnea - so please make sure you talk to your family doctor if you are having sleep disturbances as there may be some testing we need to do and something we can help you with!      KM: It is true...there are so many interconnected pieces within menopause, but we can't blame everything on it!  The mood changes can often be attributed to the perimenopausal and early post menopausal time, especially in women who have not had mood disturbances before, and in these women, we often see it improve 1-2 years after menopause.  Women with pre-existing anxiety and depression are at the most risk for worsening mood issues during the menopausal transition. Probably the number one descriptor of mood changes that I hear is an increase in a women’s “irritability”. But the midlife can be a very stressful time for women, and there are many reasons for mood changes in the midlife which may not be all attributable to hormonal changes.  AP: Vaginal dryness is often a complaint women have with menopause, can you speak about that a bit?     KM: Absolutely. This is a really important topic that I wish women felt more supported to discuss. Estrogens play an important role in our bodies and women can make several different kinds of estrogens. Tissues in a women’s vulva, vagina, lower urinary tract and bladder are very sensitive to the effects of estrogens. When those estrogens are withdrawn in menopause, this can result in something we term “genitourinary syndrome of menopause” which is a fancy name for when all those tissues become drier and less elastic. This can result in itching, bleeding, having to urinate frequently or urgently, getting recurrent urinary infections, and having pain with sexual intercourse. Unlike many other menopausal symptoms, the genitourinary symptoms often start later into menopause and will progress as a woman ages.  AP: And I also think it is important to note, that these symptoms, especially the itchiness and pain, are not always simply due to menopause, so again it is important to see your care provider to ensure it is not something else causing this!      KM: Indeed!  These changes can be very uncomfortable and distressing for women....so please do not suffer unnecessarily...come talk to us...because we can help!!! And I want to take this moment to point out that although some women may bleed in menopause because of tissue dryness, post-menopausal bleeding is never normal and other sinister causes must be ruled out. Please speak to your doctor if you are menopausal and start bleeding again. Your doctor can help you with investigations to rule out worrisome causes of post-menopausal bleeding, like certain cancers.    AP:  That’s a great reminder. Well lets chat about what we can do to help women going through menopause….    KM: First and foremost let’s talk about lifestyle modifications that women can do to help manage the menopausal transition.  Anything that cools us down can help with hot flashes - having the room at a lower temperature, using a fan, using moisture wicking sheets or clothes, dressing in layers that can easily be removed and avoiding triggers like spicy food or stress can all help. Alcohol is a huge hot flash trigger for many of my patients. And alcohol contains a lot of empty calories, so cutting back can help with weight reduction and vasomotor symptoms. We also know that excessive alcohol consumption is a risk factor for breast cancer. So that’s another important reason to stop excessive drinking. Back to the notion of weight loss, if a woman is carrying extra weight, losing weight may reduce menopausal symptoms. Another very important point is that quitting smoking can have a large impact on vasomotor symptoms, bone health and overall health for women.    AP: Beneficial for menopause and beyond!!!  Other changes that can help with mood changes, joint achiness and sleep disturbance include staying well hydrated, getting regular exercise, eating healthily and maintaining good sleep hygiene. Pulling in your support system, through what can be a challenging period in your life, is never a bad idea!! Mindfulness-based stress reduction is another tool that many women going through menopause, or other stressful times, find to be very helpful!    KM: Indeed...but most women who come to see me are suffering more than these measures can help, and that is why we often have a conversation about medications.     AP:  My understanding is that when it comes to medications, you treat based on symptom severity, so not every treatment plan is the same...is that correct?    KM: Exactly. Women are so unique. Remember that there are some menopausal women who have never had a hot flash, and some who suffer hourly!   If someone has vulvo-vaginal issues, and no other symptoms, then I will treat that, but if a woman has multiple issues the treatment plan might be much different!    AP: Shall we talk about treatment then?      KM: Yes, let’s do it. The simplest symptom to treat is vaginal dryness.  Using a good lubricant with intercourse can be enough for some women’s concerns, but others may benefit from a vaginal moisturizer or local vaginal estrogen to help with their symptoms.  Vaginal estrogens in Canada can come in the form of a cream, a vaginal suppository, or a vaginal ring that is worn daily for 3 months. Local estrogens are extremely safe and there is very minimal systemic absorption of these medications. In general, vaginal estrogens are safe for all women. They do not carry an increased risk of blood clot, or stroke. If a woman has had breast cancer, then this is a bigger conversation and I encourage her to discuss the role of local estrogens with her gynecologist and oncologist.     AP: So I have heard lots about vaginal rejuvenation.....lasers and vaginas....seems like a dangerous combination....    KM: Using lasers to treat vulvo-vaginal symptoms is a relatively new player in the menopause realm. And this is different from using lasers or surgery for cosmetic enhancement, or “rejuvenation”, of the vulva and vagina. I strongly advise women against cosmetic changes their vulva and vagina. But that is another topic for another day!  Back to menopause, there is ongoing research looking into the safety, efficacy and long-term consequences of using a laser to treat vaginal symptoms, such as dryness, in menopause. Currently, vaginal laser treatments are not covered by Pharmacare or MSP, so women pay privately to use this device.  I look forward to seeing further studies in this area so I can help women decide if investing in this treatment is appropriate and safe for them.   AP: So what if women have hot flashes as well?  Will the vaginal estrogen help those?      KM: Good question Alicia. Hot flashes are treated with either hormonal or non-hormonal systemic medications.  If hot flashes or night sweats are bothering the woman, then we will have a discussion around treatment options.  The most common treatment is an estrogen and progesterone.  There are certainly some women who should not take these medications for medical reasons, which is one of the reasons it is so important to have a good conversation with your care provider prior to starting any medications!      AP: Now you said estrogen and progesterone....isn't just estrogen the problem?      KM: In general, menopause experts believe that vasomotor symptoms are best treated with systemic estrogen. But, if we give a woman with a uterus only estrogen, we increase her risk of endometrial, or uterine cancer. The endometrium is the lining of the uterus that sloughs off every month when a woman has a period.  The reason that it sloughs off, and just doesn’t keep growing and growing is progesterone.  So to protect the lining of the uterus from thickening into a potential cancer, we use progesterone to keep the endometrium thin and healthy.     AP: I have it on good authority that progesterone can help with sleep as well!     KM: Certain forms, like micronized progesterone, are better for this than others! Many women find progesterone to be sedating, and so I always recommend that women take their progesterone at night before bed.    AP: So what is the goal with Hormone therapy?     KM: Our goal is to use the lowest dose, for an appropriate duration, to manage a woman's symptoms. This is individualized based on the woman’s symptoms.     AP: So you are not trying to get to a certain number in their hormone level?      KM: No...in fact we know that symptoms are not correlated with blood hormone levels, and I explain that to my patients by saying that a woman who has terrible hot flashes, and a woman who doesn’t know what a hot flash feels like, may have the same hormone levels! So we individualize the amount of hormone that women need (or don’t need!) based on how feel her symptoms are being controlled.  AP: So why are some practitioners checking levels, and compounding creams specific to those numbers....    KM: That’s an interesting question Alicia. Compounding hormones refers to mixing hormones in a specific base or oral preparation and then applying or ingesting those hormones. I worry about what exactly my patients are receiving when those hormones are mixed, because unlike pharmaceutical grade hormones (like pills, patches, or gels), no one is doing testing on those creams to check for components, quantities, purity, or to do batch testing. We also know that progesterone is not absorbed well across the skin, so I have major concerns when my patients come to me on progesterone creams and estrogen. No major professional organization advocates for the use of compounded hormones. Often compounded hormones are very expensive as well.     AP: So save your money and buy a new pair of shoes?     KM: Or hormones that work!    AP: Back to business.....So how can the estrogen and progesterone be taken?     KM: Well, once a woman identifies that she would like treatment for her vasomotor symptoms, we first consider reasons why it may not be safe to take systemic hormones. Although hormone therapy is extremely safe, we know that in certain cases, using menopausal hormone therapy may increase women’s chances of a blood clot, stroke and breast cancer. This is particularly true of older women, for example, over the age of 60 who have multiple health problems. After evaluating these risks, we generally prefer transdermal estrogen, which is estrogen that is given through the skin in a gel or patch. We believe that this lowers the stroke and blood clot risk associated with estrogens. Most of my patients (if they have a uterus), will use a micronized progesterone to protect their uterus and help with sleep. The exact doses and types of hormone therapy are often individualized to the woman.  AP: So we know that the HRT can help with some of the mood disturbance, but what if that is the main complaint as opposed to hot flashes?      KM: Well this is a topic you are probably better at managing than I am!! Treat the mood disturbance!! Although there are a few antidepressants that have shown some efficacy in improving hot flashes as well, so if women are suffering from mood disturbance and hot flashes and are not able to take HRT for some reason, we will try one of these medications to help manage both.  These medications include Paroxetine, Venlafaxine and Desvenlafaxine.  Now if you are on an antidepressant and not significantly affected by hot flashes, I would not switch to one of these, but if you have hot flashes, and your doctor is talking about starting an antidepressant, you could consider starting with one of these. Mood changes in menopause are not an indication for starting hormone therapy.      AP: Right, and remembering managing any mood disturbance the best place to start is talking and lifestyle optimization!  So talk to your doctor, talk to a counsellor or friend if possible, pull in your support system.  Get outdoors and exercise, make sure you are following a healthy way of eating, staying hydrated and minimizing alcohol.      KM:  Before we wrap up I just wanted to chat a bit about "natural/herbal" medication in menopause care because this is something I see a lot of. In general, I tell women that if they are using a herbal supplement and they find it helpful, then it is likely a fairly low risk thing to do. The studies show that most herbal supplements in menopause have a strong placebo effect, and women generally find their symptoms return around the 3 month mark. I see a lot of women who have tried all of the herbal supplements and not had relief of their symptoms. I once had a patient come to my office with a laundry basket full of supplements! She had tried everything, and was still having terrible hot flashes. This is common and your care provider can help you discuss medical options to help manage your symptoms more effectively.   AP: Great!  Well thanks for coming and chatting about Menopause with me....something to look forward to in the coming years!!   Keep on Growing Healthy.

On MIA Radio this week, Akansha Vaswani and Dr Peter Groot discuss Tapering Strips, a novel and practical solution for those who wish to taper gradually from a range of prescription drugs. Akansha is a doctoral candidate at the University of Massachusetts, Boston and her dissertation research will involve interviewing psychiatrists in the US about their experiences helping people stop or reduce their dose of antidepressant medication. Dr Groot is a researcher and geneticist who has led the development of Tapering Strips. In a recent study, published in the journal Psychosis, Dr Groot, together with Jim van Os, reported on the results of their trial which recorded the experiences of people using Tapering Strips. In this episode we discuss: What motivated Peter to be interested in and study the effects of coming off antidepressants drugs. That the observational study reported in Psychosis was based on questionnaires completed by users who had made use of tapering medication (Tapering Strips) to slowly reduce their medication dosage. How the questionnaire asked about withdrawal symptoms and the ease of tapering using the strips and whether people had tried to withdraw previously using conventional methods. That Tapering Strips offer a flexible and necessary addition to standard doses that have been registered by the pharmaceutical companies. That current guidelines advise doctors to let patients start on the same recommended dose of an antidepressant, without taking into account large differences that exist between patients (weight, sex, etc). How we would be surprised if, when we came to buy shoes or clothes, our choices were limited to only a few sizes, but we don’t question this limitation with our medications. How current guidelines are based on group averages and do not help a doctor to determine how a given individual patient should taper. How shared decision making, in which the patient and the doctor work in a collaborative way, can make tapering easier. How shared decision making has contributed to the success of the use of tapering medication and the availability of tapering medication makes shared decision making practically possible. How shared decision and the availability of tapering medication makes life easier for the doctor as well as for the patient. How working initially as a volunteer to develop Tapering Strips brought Peter into contact with Professor Jim van Os and the User Research Centre of Maastricht University. That, in the study, 1,750 questionnaires were sent, with 1,164 received, a response rate of 68%. Of those returned, 895 said their goal was to taper their antidepressant drug completely and 70% succeeded in this goal. That the median time taken for people in the study to withdraw from Venlafaxine was 56 days or two Tapering Strips. There were a variety of reasons reported for those who didn’t reach their goal, including the fact that some of the patients were still tapering. Other reasons reported for not withdrawing completely were due to the occurrence of withdrawal symptoms, relapse of an original condition or even issues related to reimbursement of the cost of the tapering medication by insurance companies. That 692 patients reported that previous attempts to withdraw had failed in comparison to the successful use of Tapering Strips. That people using multiple drugs should only ever taper one medication at a time and in discussion with a medical professional. That Peter’s goal for Tapering Strips is to make sure that people that want to withdrawal gradually can access Tapering Strips and have the cost reimbursed by health insurers. That Tapering Strips were not developed to get everyone off their antidepressant drug but to enable patients to get to a dosage that provides benefit for them (which can be zero) while minimising adverse effects. That people outside the Netherlands can get Tapering Medication, but only with a prescription signed by a certified doctor, instructions and receipt/order forms can be found at taperingstrip.org. That Tapering Strips are also available for antipsychotics, sedatives (benzodiazepines), analgesics and for some drugs other than psychotropics, like some anti-epileptic drugs, which are currently being developed. That Peter warns against tapering by taking doses on alternating days, particularly for drugs like paroxetine or venlafaxine that have a short metabolic half-life, because this will lead to more severe withdrawal symptoms. Relevant Links: Tapering Strips (website of the User Research Centre of Maastricht University) Treatment guidelines for the use of tapering strips Summary of the tapering study in the journal Psychosis (blog) Tapering Strips study from the journal Psychosis Peter Groot interviewed on Let's Talk Withdrawal Claire shares her experience with Tapering Strips (YouTube) Petition requesting use of Tapering Strips in the UK Mad in America report on Tapering strips study Prime Time for Shared Decision Making Mandatory Shared Decision Making © Mad in America 2018

This week, we interview Dr Peter Gordon. Dr Gordon describes himself as a gardener with an interest in medicine. He trained in both medicine and landscape architecture before specialising in psychiatry and now works with older adults in Scotland. In addition, he is an activist and campaigner and has a range of creative interests including filmmaking, photography, writing and poetry. In this interview, we walk about Peter’s own experiences of psychiatric treatment and how we need to address the divide that exists between the arts and the medical sciences. In this episode we discuss: What led Dr Gordon to have combined interests in the arts and the sciences, training both in architecture and medicine. How Peter was interested in the plurality of thinking required for psychiatry as opposed to general medicine. How he feels that his training in both the arts and the sciences led to a more rounded appreciation of why purely biological approach might miss opportunities to help people. How Peter became an activist, partly in response to the commonly taught subjective/objective diagnostic approach. How we should be focussed on the potential of any medical intervention to cause harm and should consider this carefully alongside any potential benefit. How we need to take account of all experiences to ensure we provide the maximum benefit and minimum harm to people. Peter’s own experiences with the mental health system, taking antidepressant drugs and experiencing treatment within a psychiatric hospital. How stopping his antidepressant drug resulted in withdrawal effects and led to Peter’s only episode of severe depression. Why Peter is concerned that we seem to be downplaying the experiences of people who have struggled with psychiatric drugs. How Peter’s experiences have influenced his approach to prescribing. The dominance of the biological approach and why it should not dictate how we respond to individual experiences. How the evidence is starting to show that diagnosis can often disempower and bring about ‘otherness’. Peter’s plea for people to be kind to one another and work together to maximise well-being. Relevant links: Peter’s blog: Hole Ouisa The caption is wrong Paroxetine tablets [Film-coated] Peter’s films on Vimeo Mary Midgley Nathan Filer, The Shock of the Fall Raymond Tallis To get in touch with us email: podcasts@madinamerica.com © Mad in America 2018

The post Paroxetine (Paxil) Nursing Pharmacology Considerations appeared first on NURSING.com.

This week we have an interview with Bobby Fiddaman. Bobby is a very well known author, blogger and researcher who has been writing about psychiatric drugs and the many issues involved for over 11 years. In 2011 he released his book, ‘The Evidence, However, Is Clear…The Seroxat Scandal’ which is a powerful and explosive account of his experiences taking and withdrawing from the antidepressant Seroxat.  He is a rockstar of the movement to expose the truth about psychiatric drugs, to many he is a hero and to some, he is an uncompromising agitator. His blog has been viewed over 2 million times and he is respected by many and also well known by the pharmaceutical regulators and many of the pharmaceutical manufacturers too.  I was keen to ask Bobby about his own experiences of the mental health system, his research and campaigning over the years and his relationships with the UK and US pharmaceutical regulatory bodies. In this episode we discuss: How, in the late 1990s, Bobby had health problems which made working difficult and this led to low mood and a doctor prescribing Seroxat (Paxil, Aropax, Paroxetine) How he felt that his moods and emotions were blunted by the drug and he recalls not feeling empathy or emotion That eventually his pay was stopped and he was retired on ill health grounds but by this time his financial position was difficult and he became divorced That Bobby took 21 months to wean himself off the Seroxat using a liquid form, going from 40 milligrams to 22 milligrams a day over 19 months That he then quit cold turkey, against doctor advice, because he just want to get rid of the stranglehold that the drug had on him How Bobby felt that his short term memory was affected by being on the drug That sometimes it is harder for friends and family to experience someone going through withdrawal, because they don't know what is happening to the person that they love That these experiences promoted Bobby to write his 2011 book, ‘The Evidence, However, Is Clear…The Seroxat Scandal’ How Bobby stumbled across an article by the investigative journalist Evelyn Pringle and that set the ball rolling with his own blog How Bobby’s blog started to cover the experiences of families who had experienced tragedy due to psychiatric drugs That the blog hosts guest writers so people can tell their own story in their own words How Bobby knows that the pharmaceutical manufacturers and the regulators are regular visitors to his blog That Bobby has been told that his blog makes GlaxoSmithKline ‘cringe’ and this is a measure of the impact of his work That Bobby feels that the manufacturers should just come clean and let the truth come out about the drugs, the clinical trials, the adverse effects and the withdrawal problems That many people don't understand that compensation and out of court settlements often just allow the truth to remain hidden How Bobby was present for the entire trial between Wendy Dolin and GlaxoSmithKline and was shocked by the behaviour of GSKs attorneys That the term ‘akathisia’ is not well known but is implicated in many suicides related to antidepressant and antipsychotic drugs That doctors need to listen to patients to understand the wide range of effects of the drugs That Bobby feels that the regulators, particularly the UK MHRA, should hang their heads in shame because they know about the problems with the drugs but do nothing in response That there is an incestuous relationship between the pharmaceutical manufacturers and the regulators How Bobby has had several meetings with the MHRA over the years, including meeting the CEO, but he feels that they meet to appease rather than take action in response to concerns That Bobby also set up a meeting between MHRA and Dr. David Healy  That the regulators are totally funded by the pharmaceutical industry How Bobby now highlights celebrities who promote the chemical imbalance theory of mental illness That social media has had a big impact on the ability of people to get together and share experiences and make their voices heard How the MHRA Yellow Card scheme is meant to work How, when you start asking questions about follow up, you find that no action is taken and the database of adverse events is worthless That nowhere on the labelling is a list of the benefits of antidepressant drugs That in order to make the drugs safer, we should listen to patient concerns That Bobby uses humour as a tool for getting the message heard How Bobby would like to encourage others to write about their experiences To get in touch with us email: podcasts@madinamerica.com   © Mad in America 2017  

In this episode I mention how I'm rather down on being an Aspie because of the overall results that have accumulated over life.   Over the last year or more, I have realized how Aspergers has contributed to a state of being alone, as well as learning how much I have affected others in a very painful way throughout my 20s, 30s, and 40s.   A major way I'm learning what it was like for former friends to be around with me is through daily interactions I now have with someone who exhibits severe and obvious traits of Aspergers.  I'm on the receiving end of self centered, rule based, right/wrong thinking (where others are always wrong or just stupid), and in general demeaning conversations with someone who at their core is a good person.   The net result is that I see almost exactly what it was like when I had friends who enjoyed being around me at first because they could sense what I offered in terms of interesting conversation and interactions, and then gradually they realized how painful it could be to be around me.   Even if I wasn't criticizing them, I was criticizing others and focusing conversations on how stupid other people were in various situations that often don't matter at all because they have no effect on me. Seeing all this evidence now of what it was like to be around me, I regularly suffer bouts of shame.  Unfortunatley the shame became intense when I tried to get off of the anti-anxiety medication Paroxetine, so I reverted back to my normal dose after a few weeks when I put two and two together and realized that there was a connection to the dosage level and new, painful episodes of shame that began to arise daily and which spun my brain out of control. Thanks for listening! Also dont forget to check out books.aspiecast.com which is an amazon store I set up with some of the books and other media that have left an imprint on me.  

Perzan Irani knows how difficult antidepressant withdrawal can be. When he lost his job, in 2008, he started to feel anxious. As the weeks went by, his symptoms got worse, so his doctor put him on an antidepressant. Paxil (paroxetine) is an antidepressant that belongs to group of drugs called selective serotonin reuptake inhibitors (SSRIs). Paroxetine affects chemicals in the brain that may be unbalanced in people with depression, anxiety, or other disorders. Paxil is used to treat depression, including major depressive disorder. Read the full article here: my-antidepressant-info The medication helped and he found a new career. Now that his life was stable, he thought he could stop taking his medication. The process of tapering off antidepressants, however, proved to be much more difficult than he ever imagined. He discovered he was not alone in this painful journey. His story of getting off the drugs and creating his own line of supplements to support people in antidepressant withdrawal is inspiring. His product, CleanVive, is helping people all over the world! Listen to our rich conversation: Listen on iTunes or Listen to/download this episode here: This episode is sponsored by: Please support our sponsor by visiting their site and learning more about them! Love the show? Click here to Tweet a shoutout! Want to sponsor episodes of the LIAM podcast? Click here. Mentioned in this show: Join Bruce's Mastermind Group Worry No More! book Download: Affirmations for Abundant Living LIAM Team Life Coaching Community Subscription/Social Links: Subscribe on iTunes! Subscribe on Stitcher Radio! Watch on YouTube! LIAM on Twitter: @LifeIs262 LIAM on Facebook / LifeIsAMarathon Subscribe to the LIAM Mailing List www.BruceVanHorn.com Bruce Van Horn on Twitter Bruce Van Horn on Facebook    

Perzan Irani knows how difficult antidepressant withdrawal can be. When he lost his job, in 2008, he started to feel anxious. As the weeks went by, his symptoms got worse, so his doctor put him on an antidepressant. Paxil (paroxetine) is an antidepressant that belongs to group of drugs called selective serotonin reuptake inhibitors (SSRIs). Paroxetine affects chemicals in the brain that may be unbalanced in people with depression, anxiety, or other disorders. Paxil is used to treat depression, including major depressive disorder. Read the full article here: my-antidepressant-info The medication helped and he found a new career. Now that his life was stable, he thought he could stop taking his medication. The process of tapering off antidepressants, however, proved to be much more difficult than he ever imagined. He discovered he was not alone in this painful journey. His story of getting off the drugs and creating his own line of supplements to support people in antidepressant withdrawal is inspiring. His product, CleanVive, is helping people all over the world! Listen to our rich conversation: Listen on iTunes or Listen to/download this episode here: This episode is sponsored by: Please support our sponsor by visiting their site and learning more about them! Love the show? Click here to Tweet a shoutout! Want to sponsor episodes of the LIAM podcast? Click here. Mentioned in this show: Join Bruce's Mastermind Group Worry No More! book Download: Affirmations for Abundant Living LIAM Team Life Coaching Community Subscription/Social Links: Subscribe on iTunes! Subscribe on Stitcher Radio! Watch on YouTube! LIAM on Twitter: @LifeIs262 LIAM on Facebook / LifeIsAMarathon Subscribe to the LIAM Mailing List www.BruceVanHorn.com Bruce Van Horn on Twitter Bruce Van Horn on Facebook    

Xanax, Lexomil, Prozac, Valium…Voici les psychotropes, médicaments qui agissent sur Psyché pour l’aider à calmer ses troubles. Si, de manière générale, les Français sont de grands consommateurs de médicaments, on retrouve parmi les 30 substances les plus achetées (tous médicaments confondus), 4 psychotropes : le Zolpidem, le xanax, le Zopiclone et le Paroxetine. Des antidépresseurs, des médicaments contre l’insomnie ou l’anxiété. 3 de ces 4 médicaments best-seller sont des benzodiazépines ou des dérivés de cette molécule – (le Zolpidem et le Zopiclone ne sont pas à proprement parler des benzodiazépines…

Xanax, Lexomil, Prozac, Valium…Voici les psychotropes, médicaments qui agissent sur Psyché pour l'aider à calmer ses troubles. Si, de manière générale, les Français sont de grands consommateurs de médicaments, on retrouve parmi les 30 substances les plus achetées (tous médicaments confondus), 4 psychotropes : le Zolpidem, le xanax, le Zopiclone et le Paroxetine. Des antidépresseurs, des médicaments contre l'insomnie ou l'anxiété. 3 de ces 4 médicaments best-seller sont des benzodiazépines ou des dérivés de cette molécule – (le Zolpidem et le Zopiclone ne sont pas à proprement parler des benzodiazépines et ont l'avantage de présenter moins d'inconvénients que ces derniers, notamment en termes d'effets secondaires et de dépendance – ndlr) Ces Benzodiazépines sont les psychotropes les plus consommés et les durée de prise dépassent les recommandations : la durée de prise moyenne est de 7 mois… pour une durée de prescription recommandée de 4 à 12 semaines. Des prises de médicaments parfois éloignées des recommandations, des situations de souffrance que les psychotropes soulagent mais ne guérissent pas, des interactions médicamenteuses et des effets secondaires : les psychotropes, pierre angulaire de la psychiatrie contemporaine – on dit aussi la psychopharmacologie – ces médicaments du cerveau questionnent. Pour comprendre ces situations et la place de la prescription médicamenteuse dans la psychiatrie, écoutons le point de vue des prescripteurs. Après 60 ans d'utilisation des psychotropes en médecine, quel bilan faire des médicaments de la psychiatrie ? InvitésJean-Marie Vanelle, Professeur des Universités et Praticien Hospitalier Psychiatre au CHU de Nantes.Caroline Victorri Vigneau, Maitre de Conférences à l'Université de Nantes et Praticien Hospitalier dans le service de pharmacologie clinique du CHU-Nantes. CréditsUne émission animée par Elliott Chaumont et Mathilde Robert, avec la participation de Barbara Chicotot, Valérie Fourgassié et Guillaume Mézières. A la technique, Claire Sizorn. Crédit photo : Assorted Medicine Pills in Caps ca. 2001

Theo Rein explains how the antidepressant paroxetine affects epigenetic regulation of Bdnf.

Cristina Murga and Rocio Vila-Bedmar explain why removing the kinase GRK2 prevents some of the metabolic consequences of a high-fat diet.